The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Open accessAbstract
Mycobacterium tuberculosis (M. tb), the causative agent of TB, is a recalcitrant pathogen that is rife around the world, latently infecting approximately a quarter of the worldwide population. The asymptomatic status of the dormant bacteria escalates to the transmissible, active form when the host’s immune system becomes debilitated. The current front-line treatment regimen for drug-sensitive (DS) M. tb strains is a 6-month protocol involving four different drugs that requires stringent adherence to avoid relapse and resistance. Poverty, difficulty to access proper treatment, and lack of patient compliance contributed to the emergence of more sinister drug-resistant (DR) strains, which demand a longer duration of treatment with more toxic and more expensive drugs compared to the first-line regimen. Only three new drugs, bedaquiline (BDQ) and the two nitroimidazole derivatives delamanid (DLM) and pretomanid (PMD) were approved in the last decade for treatment of TB—the first anti-TB drugs with novel mode of actions to be introduced to the market in more than 50 years—reflecting the attrition rates in the development and approval of new anti-TB drugs. Herein, we will discuss the M. tb pathogenesis, current treatment protocols and challenges to the TB control efforts. This review also aims to highlight several small molecules that have recently been identified as promising preclinical and clinical anti-TB drug candidates that inhibit new protein targets in M. tb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 2×
“RIF binds to the ꞵ-subunit of the bacterial RNA polymerase and exerts its bactericidal activity by inhibiting the early steps of gene transcription [22,23].”
BackgroundThe challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Yee, D., Valiquette, C., Pelletier, M., Parisien, I., Rocher, I., & Menzies, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-626oc · Cited by 840
Foamy macrophages and the progression of the human tuberculosis granuloma
Russell, D. G., Cardona, P.-J., Kim, M.-J., Allain, S., & Altare, F. (2009) · Nature Immunology · doi:10.1038/ni.1781 · Cited by 827
Tuberculosis and HIV Co-Infection
Pawlowski, A., Jansson, M., Sköld, M., Rottenberg, M. E., & Källenius, G. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002464 · Cited by 764
Peyron, P., Vaubourgeix, J., Poquet, Y., Levillain, F., Botanch, C., Bardou, F., Daffé, M., Emile, J.-F., Marchou, B., Cardona, P.-J., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000204 · Cited by 751
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Mycobacterium tuberculosis: success through dormancy
Gengenbacher, M., & Kaufmann, S. H. E. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00331.x · Cited by 696
Mycolic Acids: Structures, Biosynthesis, and Beyond
Marrakchi, H., Lanéelle, M.-A., & Daffé, M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.11.011 · Cited by 623
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3262 · Cited by 603
The curious characteristics of pyrazinamide: a review.
Zhang, Y., & Mitchison, D. A. (2003) · PubMed · Cited by 586
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Tahlan, K., Wilson, R., Kastrinsky, D. B., Arora, K., Nair, V., Fischer, E., Barnes, S. W., Walker, J. R., Alland, D., Barry, C. E., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05708-11 · Cited by 504
Tuberculosis: Latency and Reactivation
Flynn, J. L., & Chan, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.7.4195-4201.2001 · Cited by 500
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442
Tuberculosis Pathogenesis and Immunity
Philips, J. A., & Ernst, J. D. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132458 · Cited by 416
Portevin, D., de Sousa-D'Auria, C., Houssin, C., Grimaldi, C., Chami, M., Daffé, M., & Guilhot, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305439101 · Cited by 390
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
Makarov, V., Lechartier, B., Zhang, M., Neres, J., van der Sar, A. M., Raadsen, S. A., Hartkoorn, R. C., Ryabova, O. B., Vocat, A., Decosterd, L. A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303575 · Cited by 380
Pulmonary Tuberculosis: The Essentials
Leung, A. N. (1999) · Radiology · doi:10.1148/radiology.210.2.r99ja34307 · Cited by 366
Update on pulmonary disease due to non-tuberculous mycobacteria
Stout, J. E., Koh, W.-J., & Yew, W. W. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.03.006 · Cited by 355
Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330
History of the Development of Rifampin
Sensi, P. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s402 · Cited by 315
Acharya, B., Acharya, A., Gautam, S., Ghimire, S. P., Mishra, G., Parajuli, N., & Sapkota, B. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05413-7 · Cited by 292
Challenges in tuberculosis drug research and development
Ginsberg, A. M., & Spigelman, M. (2007) · Nature Medicine · doi:10.1038/nm0307-290 · Cited by 283
Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of Action
Sacksteder, K. A., Protopopova, M., Barry, C. E., Andries, K., & Nacy, C. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.56 · Cited by 269
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target
Zhang, B., Li, J., Yang, X., Wu, L., Zhang, J., Yang, Y., Zhao, Y., Zhang, L., Yang, X., Yang, X., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.003 · Cited by 263
Pathology of post primary tuberculosis of the lung: An illustrated critical review
Hunter, R. L. (2011) · Tuberculosis · doi:10.1016/j.tube.2011.03.007 · Cited by 256
Luies, L., & du Preez, I. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-20 · Cited by 244
Tuberculosis Treatment and Drug Regimens
Sotgiu, G., Centis, R., D'ambrosio, L., & Migliori, G. B. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017822 · Cited by 241
Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075245 · Cited by 241
Bhatt, A., Molle, V., Besra, G. S., Jacobs, W. R., & Kremer, L. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05761.x · Cited by 234
Migliori, G. B., Tiberi, S., Zumla, A., Petersen, E., Chakaya, J. M., Wejse, C., Muñoz Torrico, M., Duarte, R., Alffenaar, J. W., Schaaf, H. S., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.042 · Cited by 231
Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary
Grosset, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.833-836.2003 · Cited by 224
Zumla, A., Chakaya, J., Centis, R., D'Ambrosio, L., Mwaba, P., Bates, M., Kapata, N., Nyirenda, T., Chanda, D., Mfinanga, S., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00063-6 · Cited by 219
MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212
La Rosa, V., Poce, G., Canseco, J. O., Buroni, S., Pasca, M. R., Biava, M., Raju, R. M., Porretta, G. C., Alfonso, S., Battilocchio, C., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05270-11 · Cited by 212
MmpL Genes Are Associated with Mycolic Acid Metabolism in Mycobacteria and Corynebacteria
Varela, C., Rittmann, D., Singh, A., Krumbach, K., Bhatt, K., Eggeling, L., Besra, G. S., & Bhatt, A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.03.006 · Cited by 210
MmpL3 is the flippase for mycolic acids in mycobacteria
Xu, Z., Meshcheryakov, V. A., Poce, G., & Chng, S.-S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700062114 · Cited by 201 · cited 21×
“The fundamental role of MmpL3 in shuttling the MAs across the cytoplasmic membrane and, accordingly, forging the formidable permeability barrier of M. tb was verified in different reports [91–95].”
BackgroundInfluentialPortevin, D., de Sousa-D'Auria, C., Montrozier, H., Houssin, C., Stella, A., Lanéelle, M.-A., Bardou, F., Guilhot, C., & Daffé, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m408578200 · Cited by 190
Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13
Aggarwal, A., Parai, M. K., Shetty, N., Wallis, D., Woolhiser, L., Hastings, C., Dutta, N. K., Galaviz, S., Dhakal, R. C., Shrestha, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.025 · Cited by 183
The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
Mdluli, K., Kaneko, T., & Upton, A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021154 · Cited by 180
Stec, J., Onajole, O. K., Lun, S., Guo, H., Merenbloom, B., Vistoli, G., Bishai, W. R., & Kozikowski, A. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00415 · Cited by 170
Mycobacterium tuberculosis: An Adaptable Pathogen Associated With Multiple Human Diseases
Chai, Q., Zhang, Y., & Liu, C. H. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00158 · Cited by 170
Gande, R., Gibson, K. J. C., Brown, A. K., Krumbach, K., Dover, L. G., Sahm, H., Shioyama, S., Oikawa, T., Besra, G. S., & Eggeling, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408648200 · Cited by 168
Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis
Dorhoi, A., & Kaufmann, S. H. E. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0531-3 · Cited by 167
Louw, G. E., Warren, R. M., Gey van Pittius, N. C., Leon, R., Jimenez, A., Hernandez-Pando, R., McEvoy, C. R. E., Grobbelaar, M., Murray, M., van Helden, P. D., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1924oc · Cited by 166
DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization
Brecik, M., Centárová, I., Mukherjee, R., Kolly, G. S., Huszár, S., Bobovská, A., Kilacsková, E., Mokošová, V., Svetlíková, Z., Šarkan, M., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00237 · Cited by 164
Shirude, P. S., Shandil, R., Sadler, C., Naik, M., Hosagrahara, V., Hameed, S., Shinde, V., Bathula, C., Humnabadkar, V., Kumar, N., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401382v · Cited by 164
Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
Rao, S. P. S., Lakshminarayana, S. B., Kondreddi, R. R., Herve, M., Camacho, L. R., Bifani, P. J., Kalapala, S. K., Jiřiček, J., Ma, N. L., Tan, B. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007355 · Cited by 163
Indoleamides are active against drug-resistant Mycobacterium tuberculosis
Lun, S., Guo, H., Onajole, O. K., Pieroni, M., Gunosewoyo, H., Chen, G., Tipparaju, S. K., Ammerman, N. C., Kozikowski, A. P., & Bishai, W. R. (2013) · Nature Communications · doi:10.1038/ncomms3907 · Cited by 160
Self-citationDrug‐resistant tuberculosis: Past, present, future
CHIANG, C., CENTIS, R., & MIGLIORI, G. B. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01738.x · Cited by 159
Deidda, D., Lampis, G., Fioravanti, R., Biava, M., Porretta, G. C., Zanetti, S., & Pompei, R. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.3035 · Cited by 159
Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis
Chikhale, R. V., Barmade, M. A., Murumkar, P. R., & Yadav, M. R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00281 · Cited by 158
The Arabinosyltransferase EmbC Is Inhibited by Ethambutol in Mycobacterium tuberculosis
Goude, R., Amin, A. G., Chatterjee, D., & Parish, T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00162-09 · Cited by 157
The Polyketide Synthase Pks13 Catalyzes a Novel Mechanism of Lipid Transfer in Mycobacteria
Gavalda, S., Bardou, F., Laval, F., Bon, C., Malaga, W., Chalut, C., Guilhot, C., Mourey, L., Daffé, M., & Quémard, A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.10.011 · Cited by 148
MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine
Su, C.-C., Klenotic, P. A., Bolla, J. R., Purdy, G. E., Robinson, C. V., & Yu, E. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901346116 · Cited by 148
Remuiñán, M. J., Pérez‐Herrán, E., Rullás, J., Alemparte, C., Martínez-Hoyos, M., Dow, D. J., Afari, J., Mehta, N., Esquivias, J., Jiménez, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060933 · Cited by 146
The Pks13/FadD32 Crosstalk for the Biosynthesis of Mycolic Acids in Mycobacterium tuberculosis
Gavalda, S., Léger, M., van der Rest, B., Stella, A., Bardou, F., Montrozier, H. L., Chalut, C., Burlet‐Schiltz, O., Marrakchi, H., Daffé, M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.006940 · Cited by 145
ATP synthase in mycobacteria: Special features and implications for a function as drug target
Lü, P., Lill, H., & Bald, D. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.01.022 · Cited by 130
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3
Li, W., Obregón‐Henao, A., Wallach, J. B., North, E. J., Lee, R. E., Jr., Juarrero, M. G., Schnappinger, D., & Jackson, M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-16 · Cited by 123
Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression
Degiacomi, G., Benjak, A., Madacki, J., Boldrin, F., Provvedi, R., Palù, G., Korduláková, J., Cole, S. T., & Manganelli, R. (2017) · Scientific Reports · doi:10.1038/srep43495 · Cited by 122
Sutherland, H. S., Tong, A. S. T., Choi, P. J., Blaser, A., Conole, D., Franzblau, S. G., Lotlikar, M. U., Cooper, C. B., Upton, A. M., Denny, W. A., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.026 · Cited by 119
Chahine, E. B., Karaoui, L. R., & Mansour, H. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504087 · Cited by 114
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening
Manjunatha, U. H., & Smith, P. W. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.031 · Cited by 111
Stanley, S. A., Kawate, T., Iwase, N., Shimizu, M., Clatworthy, A. E., Kazyanskaya, E., Sacchettini, J. C., Ioerger, T. R., Siddiqi, N., Minami, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302114110 · Cited by 109
1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis
Chatterji, M., Shandil, R. K., Manjunatha, M. R., Solapure, S. M., Ramachandran, V., Kumar, N., Saralaya, R., Panduga, V., Reddy, J., Prabhakar, K. R., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03233-14 · Cited by 107
The structure–activity relationship of urea derivatives as anti-tuberculosis agents
Brown, J. R. C., North, E. J., Hurdle, J. G., Morisseau, C. H. P., Scarborough, J. S., Sun, D., Korduláková, J., Scherman, M. S., Jones, V. M., Grzegorzewicz, A. E., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.034 · Cited by 106
Direct Inhibition of MmpL3 by Novel Antitubercular Compounds
Li, W., Stevens, C. M., Pandya, A. N., Darzynkiewicz, Z., Bhattarai, P., Tong, W., Gonzalez-Juarrero, M., North, E. J., Zgurskaya, H. I., & Jackson, M. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00048 · Cited by 97
Kolly, G. S., Boldrin, F., Sala, C., Dhar, N., Hartkoorn, R. C., Ventura, M., Serafini, A., McKinney, J. D., Manganelli, R., & Cole, S. T. (2014) · Molecular Microbiology · doi:10.1111/mmi.12546 · Cited by 94
Zhang, W. Y., Lun, S., Wang, S.-H., Jiang, X.-W., Yang, F., Tang, J., Manson, A. L., Earl, A. M., Gunosewoyo, H., Bishai, W. R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01319 · Cited by 90
Self-citationLead Optimization of 1,4-Azaindoles as Antimycobacterial Agents
Shirude, P. S., Shandil, R. K., Manjunatha, M. R., Sadler, C., Panda, M., Panduga, V., Reddy, J., Saralaya, R., Nanduri, R., Ambady, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500571f · Cited by 89
Locher, C. P., Jones, S. M., Hanzelka, B. L., Perola, E., Shoen, C. M., Cynamon, M. H., Ngwane, A. H., Wiid, I. J. F., van Helden, P. D., Betoudji, F., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04347-14 · Cited by 87
Delamanid or pretomanid? A Solomonic judgement!
Mudde, S. E., Upton, A. M., Lenaerts, A. J. M., Bax, H. I., & de Steenwinkel, J. E. M. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab505 · Cited by 85
Lu, X., Williams, Z. C., Hards, K., Tang, J., Cheung, C., Aung, H. L., Wang, B., Liu, Z., Hu, X., Lenaerts, A. J. M., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00225 · Cited by 83
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis
Makarov, V., Neres, J., Hartkoorn, R. C., Riabova, O., Kazakova, E., Šarkan, M., Huszár, S., Piton, J., Kolly, G. S., Vocat, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00778-15 · Cited by 81
The Pathogenesis of Tuberculosis
Schluger, N. W. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.f293 · Cited by 80
Identifying Vulnerable Pathways in Mycobacterium tuberculosis by Using a Knockdown Approach
Carroll, P., Faray-Kele, M.-C., & Parish, T. (2011) · Applied and Environmental Microbiology · doi:10.1128/aem.02880-10 · Cited by 76
The quest for the holy grail: new antitubercular chemical entities, targets and strategies
Huszár, S., Chibale, K., & Singh, V. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.02.003 · Cited by 72
Reece, S. T., & Kaufmann, S. H. E. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.10.006 · Cited by 67
Kawate, T., Iwase, N., Shimizu, M., Stanley, S. A., Wellington, S., Kazyanskaya, E., & Hung, D. T. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.035 · Cited by 64
Structure of the Essential Mtb FadD32 Enzyme: A Promising Drug Target for Treating Tuberculosis
Kuhn, M. L., Alexander, E. M., Minasov, G., Page, H. J., Warwrzak, Z., Shuvalova, L., Flores, K. J., Wilson, D. J., Shi, C., Aldrich, C. C., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00082 · Cited by 54
Zhang, W. Y., Lun, S., Liu, L., Xiao, S., Duan, G., Gunosewoyo, H., Yang, F., Tang, J., Bishai, W. R., & Yu, L.-F. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00010 · Cited by 46
Self-citationTima, H. G., Dulayymi, J. R. A., Denis, O., Lehebel, P., Baols, K. S., Mohammed, M. O., L’homme, L., Sahb, M. M., Potemberg, G., Legrand, S., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000450955 · Cited by 40
Crystal structure of FadD32, an enzyme essential for mycolic acid biosynthesis in mycobacteria
Li, W., Gu, S., Fleming, J., & Bi, L. (2015) · Scientific Reports · doi:10.1038/srep15493 · Cited by 32
Structure-Based Drug Design for Tuberculosis: Challenges Still Ahead
Bruch, E. M., Petrella, S., & Bellinzoni, M. (2020) · Applied Sciences · doi:10.3390/app10124248 · Cited by 18
Cited by
The Role of Osteopontin in Respiratory Health and Disease
Barkas, G. I., & Kotsiou, O. S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13081259 · Cited by 16
Metadata
- Authors
- Alsayed, S. S. R., & Gunosewoyo, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-03-08
- Volume
- 24
- Issue
- 6
- Pages
- 5202
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4323666971
- Cited by
- 332
- References
- 87
- FWCI
- 62.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.